Population Pharmacokinetics Analysis of Infliximab in up to 10-Year-Old Patients with Paediatric Inflammatory Bowel Disease: Label-Recommended Dose Fails to Achieve Therapeutic Target Concentration
{{output}}
Background and objectives: Younger patients with paediatric inflammatory bowel disease (IBD) may require higher infliximab (IFX) doses to attain similar target trough levels compared with older paediatric and adult patients with ... ...
